Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody

Journal

Oncotarget
ISSN: 1949-2553
Titre abrégé: Oncotarget
Pays: United States
ID NLM: 101532965

Informations de publication

Date de publication:
20 Aug 2019
Historique:
entrez: 7 9 2019
pubmed: 7 9 2019
medline: 7 9 2019
Statut: epublish

Résumé

[This corrects the article DOI: 10.18632/oncotarget.21660.].

Identifiants

DOI: 10.18632/oncotarget.27162 PMID: 31489122 PMC: PMC6707946
pubmed: 31489122
doi: 10.18632/oncotarget.27162
pii: 27162
pmc: PMC6707946
doi:

Types de publication

Published Erratum

Langues

eng

Pagination

5120-5122

Commentaires et corrections

Type : ErratumFor

Auteurs

Laurence Booth (L)

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA.

Jane L Roberts (JL)

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA.

Andrew Poklepovic (A)

Department of Medicine, Virginia Commonwealth University, Richmond, VA 23298, USA.

Francesca Avogadri-Connors (F)

Puma Biotechnology Inc., Los Angeles, CA 90024, USA.

Richard E Cutler (RE)

Puma Biotechnology Inc., Los Angeles, CA 90024, USA.

Alshad S Lalani (AS)

Puma Biotechnology Inc., Los Angeles, CA 90024, USA.

Paul Dent (P)

Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA.

Classifications MeSH